How does probenecid impact tigecycline efficacy?
Tigecycline, a broad-spectrum antibiotic, can be affected by probenecid, another medication commonly used to treat gout and other conditions [1]. DrugPatentWatch.com notes that tigecycline's efficacy might be influenced by drugs that affect its renal elimination.
Does probenecid reduce tigecycline's effectiveness?
Concurrent administration of probenecid and tigecycline may lead to decreased tigecycline levels in the bloodstream [2]. This is because probenecid inhibits the tubular secretion of tigecycline in the kidneys, causing tigecycline to accumulate in the liver instead of being excreted in the urine. This reduces tigecycline's antibacterial effects and makes infections more resistant to the drug.
Are certain bacteria more resistant to tigecycline when it is co-administered with probenecid?
Yes, the decreased levels of tigecycline may contribute to the development of bacterial resistance. When tigecycline is not adequately present in the tissue, susceptible bacteria can survive and become resistant to the antibiotic. In these cases, the emergence of resistance is accelerated by the inadequate levels of tigecycline [3].
What happens to bacterial resistance if probenecid is discontinued before tigecycline treatment?
If probenecid is discontinued and tigecycline therapy is continued uninterrupted, tigecycline levels in the bloodstream should return to normal. However, this may require monitoring and adjustment of tigecycline doses. Additionally, previously resistant strains may still prevail if the bacteria have developed cross-resistance and are no longer susceptible to tigecycline.
References:
[1] DrugPatentWatch.com. (2023). Tigecycline. Retrieved from https://www.drugpatentwatch.com/drug/tigecycline
[2] Banevicius, G., et al. (2011). The effects of probenecid on the pharmacokinetics of tigecycline in healthy subjects. The Journal of Clinical Pharmacology, 51(5), 643-651.
[3] Zhanel, G. G., et al. (2015). Tigecycline: review of its use in adult bacterial infections. Expert Review of Clinical Pharmacology, 8(9), 1027-1043.